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Abstract
Background: Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a
median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in
progression-free survival, but not in overall survival.
Methods: We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to
determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we
used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a
cohort of GBM patients before and during bevacizumab treatment.
Results: We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would
probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of
bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and
serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a
correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance.
Conclusions: Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in
Glioblastoma treatment.
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Background
Glioblastoma (GBM), a grade IV glioma according to the
World Health Organization (WHO) classification, is one
of the most common, aggressive, and highly vascularized
brain tumors in adults, with a median survival of 20.9
months and an incidence rate of 3–4 newly diagnosed pa-
tients per 100,000 population [1–3]. The gold standard
treatment consists of a maximal surgical resection,
followed by radiotherapy with concomitant and adjuvant
chemotherapy with temozolomide [4]. Recently, it has
been observed that using tumor-treating field (TTField)
maintenance in combination with temozolomide has im-
proved GBM overall survival (OS) with minor side effects
[3]. However, despite advances in surgical techniques and
efforts in the development of new drugs, increasing pa-
tient survival rates is still a challenge.
GBMs are characterized by their low tumor cell differen-
tiation, high proliferation and intracranial dissemination, el-
evated cellular heterogeneity, and abundant normal and
aberrant vasculature [1, 5]. Pathological neovascularization
is mostly triggered by hypoxia through the expression of
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vascular endothelial growth factor (VEGF) [6], which pro-
motes angiogenesis, vasculogenesis, and vascular mimicry,
cellular and molecular mechanisms that usually overlap
each other [7].
Anti-angiogenic therapies have been shown to
normalize the structure and function of tumor-
associated blood vessels [8]. Bevacizumab (Avastin®,
Genentech/Roche), a recombinant humanized IgG1
monoclonal antibody that prevents the interaction of
VEGFA with its receptors and inhibits downstream sig-
naling pathways [9], was the first anti-angiogenic im-
munotherapy agent approved by the FDA to be used in
GBM and in other cancer pathologies [10]. Bevacizumab
blocks the autocrine and paracrine VEGF signaling and
reduces vessel leakiness and pressures within the brain
tumor, triggering a vasogenic edema reduction and, con-
sequently, lowering corticosteroid administration [11,
12]. Additionally, it may lead to vessel regression, thus
depriving cancers of their nutrient source, which in turn
may synergize the response to chemotherapy [13, 14].
However, some phase II and phase III clinical trials per-
formed with bevacizumab in newly diagnosed (AVAglio-
B021990 and RTOG-0825) and recurrent GBM patients
failed to demonstrate a significant OS advantage, while
revealing strong evidence of prolonged progression-free
survival in GBM [15–19]. Indeed, the same results were
observed in a recent meta-analysis carried out by
Cochrane, in which authors emphasize that none of the
clinical assays address the possibility that subsets of pa-
tients with GBM may benefit from bevacizumab therapy
[20]. Additionally, some GBM tumors grow in an
angiogenesis-independent manner suggesting that these
patients would probably respond poorly to anti-
angiogenic therapy. Therefore, it is essential to identify a
patient subpopulation that will benefit from the bevaci-
zumab treatment [21]. Although some predictive bio-
markers have been suggested to be measured in plasma
[22] and in solid biopsies [23], more robust and effi-
cient biomarkers are needed to identify responder and
non-responder patient subpopulations as well as to
personalize the bevacizumab doses required to achieve
antitumor effectiveness in the responder group.
We found that VEGFA expression levels could be used
to calculate the specific dose of bevacizumab needed to in-
crease the response to bevacizumab treatment. Addition-
ally, GBM cell lines and patients with initial high VEGFA
levels were more likely to respond positively to this anti-
angiogenic therapy than other subpopulations of GBM
with low VEGFA expression-secretion levels. Moreover, in
a small cohort of GBM patients, we observed that VEGFA
levels in serum, but not in plasma, correlated with re-
sponse to bevacizumab treatment. Our data suggest that
analyzing VEGFA levels in serum could be useful as a pre-
dictive biomarker to identify GBM patients that may
benefit from bevacizumab treatment as well as to guide
the recommended dosage.
Methods
Cell lines and culture
Three immortalized GBM cell lines (LN229, U87, and
U373), human brain microvascular endothelial cells
(HBMECs), and human mesenchymal stem cells
(hMSCs) (a gift from Dr. Carmen Escobedo Lucea) were
used. These cell lines were cultured in Dulbecco’s modi-
fied Eagles’ medium (DMEM) supplemented with 10%
fetal bovine serum and 100 units/ml penicillin and 100
mg/ml streptomycin and were cultured in parallel at
normoxia (21% O2) and hypoxia (1% O2). The GBM 12
OCT primary line was provided by Pilar Sanchez Gómez
(Instituto de Salud Carlos III-UFIEC) [24], and HBMECs
were isolated following the protocol published by Stins
and colleagues [25].
Cancer stem cells (GBM27, GBM123, GBM128D,
GBM38, GBM128B, and GBM18) were isolated from
GBM surgical samples and cultured according to the
protocol described previously [26]. Tissue samples were
obtained from patients operated at the Neurosurgery
Department of Hospital Universitario la Fe (Valencia,
Spain).
Bevacizumab treatment in vitro
Cells were grown for 72 h, and levels of VEGFA basal se-
cretion were calculated by enzyme-linked immunosorb-
ent assay (ELISA). Then, the amount of bevacizumab
(Avastin®, Roche) needed to neutralize the VEGFA secre-
tion was calculated in each case (Additional file: material
and methods section).
Enzyme-linked immunosorbent assay (ELISA)
Basal levels of VEGFA in vitro or total serum levels iso-
lated from mice and humans were calculated by ELISA,
according to the VEGF Human ELISA Kit manufac-
turer’s instructions (Invitrogen). Absorbance detec-
tion was performed at 450 nm using a microplate
reader.
RT and QRT-PCR
For RT-PCR, total RNA was isolated using RNeasy Mini
or Micro kit (QIAGEN) following the manufacturer’s
recommendations. One microgram of RNA was used for
cDNA synthesis (High-Capacity cDNA Reverse Tran-
scription Kit; Applied BioSystems). QRT-PCR reactions
were performed in an optical 384-well plate equipped
with an ABI PRISM 7900 HT sequence detection system
(Applied Biosystems) using SYBR Green. Gene expres-
sion levels were quantified using the primers listed in
Table 1, and two housekeeping genes were used to
normalize the data.
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Protein isolation and Western blotting
Cells and tumor specimens were lysed with radioimmu-
noprecipitation assay buffer (RIPA) containing a prote-
ase and phosphatase inhibitor cocktail (Roche). After
centrifugation, the supernatant was collected and quanti-
fied using the BCA Protein Assay Kit (Calbiochem). Pro-
tein extracts were then separated by 12% SDS-PAGE
and transferred to nitrocellulose membranes. After
blocking for 1 h with 10% bovine serum albumin in T-
TBS, the membranes were incubated with primary anti-
body against VEGFA (ab46154) overnight at 4 °C. After
washing, the membranes were incubated with the corre-
sponding peroxidase-labeled secondary antibody. Detec-
tion was performed using ECL reagents according to the
manufacturer’s guidelines. Band intensities were quanti-
fied using Quantity One software (Bio-Rad Laboratories,
Inc.) and were standardized to β-actin or GAPDH levels.
Immunofluorescence staining
Cells were cultured in chamber slides and then fixed
with 4% paraformaldehyde. After blocking for 1 h at
room temperature (RT) with 10% BSA and 0.05% Triton
X-100 in PBS, staining was performed using rabbit
monoclonal anti-VEGFA (1:200, ab52917) followed by
overnight incubation at 4 °C. Slides were washed and in-
cubated for 1 h at RT with secondary antibody Alexa
555 goat anti-rabbit (1:200, Invitrogen) and Alexa Fluor
647 Phalloidin (1:100, Invitrogen). Then, the nuclei were
stained with DAPI, (1:5000, Sigma-Aldrich), and slides
were mounted with fluorescence mounting medium
FluorSave™ reagent (Millipore). Fluorescence was ob-
served under a Leica TCS SPE-inverted confocal micro-
scope in the Confocal Unit of IiSGM. The experiment
was performed twice, and in each event, three images of
the different types of cells were taken. Negative controls
with the secondary antibodies were carried out in all
cases.
Tumor tissue sections were immersed in a 5% blocking
solution of the specific serum and then incubated (over-
night, 4 °C) in solutions containing the following primary
antibodies: goat anti-mouse CD105 (R&D Systems) and
mouse anti-human vimentin (Santa Cruz Biotechnol-
ogy). Then, Alexa Fluor-conjugated secondary antibodies
were used for 1 h (donkey anti-goat 555 and goat anti-
mouse 488), and then the nuclei were counterstained
with DAPI and coverslips were mounted using Fluor-
Save™ reagent (Millipore). The immunofluorescence re-
sults were quantified using the Image-Pro Plus software
where the fluorescence intensity of CD105 and VEGFA
was calculated.
Conditioned media
To produce conditioned media (CM), LN229, U87, and
U373 were cultured for 72 h in the presence of IgG and
standard or specific doses of bevacizumab. CM was
sterile-filtered and stored at − 80 °C until use.
Tube formation
Matrigel™ Matrix High Concentration (BD Biosciences)
was diluted with DMEM and used to coat 96-well plates
at 37 °C for 30 min. Then, 2 × 104 HBMECs were resus-
pended in conditioned media DMEM 1:1 and seeded
onto the Matrigel. The tube formation ability was mea-
sured after O/N incubation. The total length of the tubes
and the number of branches were quantified using
ImageJ.
Table 1 Primers used to quantify gene expression levels














β-2 microglobulin GCACGCAGAAAGAAATAGCA CAGAGGGTTTGGCATATGAT
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Transwell migration assay
To evaluate cell migration, a 24-well plate with 8-μm
pore size polycarbonate membrane inserts was used. Ap-
proximately 7.5 × 104 HBMECs were resuspended in
100 μl serum-free DMEM medium and seeded in the
upper chamber, and 500 μl of conditioned media was
added to the lower chamber. After 3 h, the migrated cells
were fixed with 4% paraformaldehyde and stained with
0.1% crystal violet. All experiments were performed in
triplicate.
Wound healing assay
HBMECs were seeded in a 24-well plate overnight. The
medium was removed, and the cells were washed twice
with DMEM. A linear wound was created dragging a
200-μl pipette tip across the surface. Conditioned media
from U87, U373, and LN229 cell lines with and without
standard and specific doses of bevacizumab were added.
The wound area was photographed with phase contrast
at 0 h, and cells were allowed to migrate for 7 h.
Scratched areas were measured with the ImageJ soft-
ware, and the percent of wound closure was calculated.
xCELLigence real-time cell analysis (RTCA): migration
4 × 104 HBMECs were seeded per well into E16 plates
(Roche) in DMEM, and conditioned media were loaded
to the lower chamber. Then, the E16 plates were equili-
brated to 37 °C and placed into the xCELLigence system.
The impedance was recorded in 15min intervals for 72
h, and the total number of cells migrating was quantified
using a cell index.
In vivo Matrigel plug assay
Conditioned media of each cell line were concentrated
using Amicon Ultra-15 (Millipore). Then, 150 μl of
media concentrate was mixed with 350 μl Matrigel (BD
Bioscience) and heparin. The mixture was injected sub-
cutaneously into the flanks of 6-week-old immunodefi-
cient mice (N = 5 mice per group). Mice were sacrificed
after 7 days, and Matrigel plugs were removed.
Histopathology
Matrigel plugs and tumor tissues were fixed in 4% para-
formaldehyde and embedded in paraffin, and 4-μm slices
were obtained. The slides were stained with hematoxylin
and eosin (H&E). Masson Trichrome Goldner staining
was performed according to the manufacturer’s instruc-
tions (Bio Optica).
Heterotopic xenograft assay and bevacizumab treatment
1.5 × 106 LN229, U87, and U373 cells were resuspended in
culture media, mixed with cold liquid Matrigel (BD), and
then subcutaneously injected into athymic nude mice (N =
10 per group). Following Baumgarten’s recommendations
for dose conversion between human/iv and mice/ip [27],
specific and standard doses were calculated using in vitro
hypoxic basal secretion. Final concentrations used were as
follows: 60mg/kg (U373-specific dose), 34mg/kg (U87-spe-
cific dose), 10mg/kg (LN229-specific dose), and 16.6mg/kg
bodyweight (standard dose). A control group (N = 10) re-
ceived human polyclonal immunoglobulin (IgG, Intratect)
at the same concentration as bevacizumab. Tumor volumes
were measured with a caliper when they reached a visible
size, and mice were euthanized when tumor burden be-
came symptomatic.
Tissue microarray (TMA)
Eighty-seven tissue blocks were evaluated by a patholo-
gist for the presence of malignant sections. Tumors were
graded following the World Health Organization classifi-
cation and divided into LGG and GBM (Additional file 1:
Tables S1-2). Six TMAs were constructed from those
formalin-fixed paraffin-embedded (FFPE) tissues using
an arraying instrument (GALILEO CK 3500). Three tis-
sue cores (0.6–1 mm diameter each) were made from
each tissue block. Then, TMA blocks were cut at 4 μm
and stained with hematoxylin & eosin. VEGFA signal
was scored as follows: 0 = rare, 1 = localized, and 2 =
diffuse.
Immunohistochemistry
FFPE and TMA sections were stained (as per the manu-
facturer’s staining protocol) with the Bond Polymer Re-
fine Detection Kit on a Bond-max™ fully automated
staining system (Leica Microsystems GmbH, Germany),
using a rabbit polyclonal antibody against VEGFA (1:
100, ab46154).
Human samples
Solid surgical tissue samples and peripheral blood from
patients and healthy donors were obtained from patients
operated at HM Hospitales (HM), Madrid, Spain; Bio-
banco La Fe (PT17/0015/0043), Hospital Universitario la
Fe (HUlaFe), Valencia, Spain; and the HGM BioBank, in-
tegrated in RETICS, National Network Biobanks, fund-
ing by Instituto de Salud Carlos III (Additional file 1:
Tables S1-2). Peripheral blood samples from patients
were collected prior to surgery, or prior and during
Avastin treatment. These blood samples were left to clot
for 30 min at room temperature, and the serum was iso-
lated and stored at − 80 °C until use.
MRI
MR images were obtained using a 3-T MRI scanner
(Achieva Intera 3T; Philips Healthcare, Best, the
Netherlands) and 8-channel SENSE head coil. For DCE-
MRI, baseline T1-weighted images were obtained with
the following parameters: TR 3.5 ms, TE 1.7 ms, slice
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thickness 3.5 mm, field of view (FOV) 230 mm, matrix
size of 116 × 117, 30 volumes, temporal resolution 5.7 s,
and flip angles of 5° and 10° to create two pre-contrast
datasets. Then, a DCE perfusion imaging dynamic series
was performed using T1-weighted sequences with the
same MR parameters except for an increased flip angle
of 10°. At the end of the third volume acquisition, a
bolus of 3 ml of gadolinium (Gd)-based contrast agent
(gadobutrol 1 mmol/ml) was injected intravenously at a
rate of 3 ml/s.
Structural contrast 3D T1 fast field echo (FFE) se-
quence was then performed, and the detail parameters
were as follows: TR/TE = 5.8/2.7 ms, flip angle 8°, FOV
240 × 192 mm, matrix size 240 × 192, and reconstructed
voxel size of 1 × 1 × 1mm.
At that point, a T2-weighted perfusion MRI was per-
formed. At the end of the third volume acquisition, a
bolus of 6 ml of gadolinium was injected intravenously
at a rate of 5 ml/s. The sequence was done with the fol-
lowing parameters: TR 17ms, TE 25ms, slice thickness
3.5 mm, field of view (FOV) 230 × 184 mm, matrix size
of 80 × 60, 30 volumes, temporal resolution 2.6 s, and flip
angles of 7°.
Parametric maps of cerebral blood volume (CBV) were
acquired, and regional CBV values were calculated by a
region of interest analysis between tumor and normal
tissue. To observe BBB permeability, vascular constant
transfer (Ktrans min− 1) values were calculated using syn-
go.via (Software Product Line for 3D Routine and Ad-
vanced Reading Siemens Healthcare). One region of
interest was manually positioned on the solid tumoral
area with maximal Ktrans value and compared with
contralateral white matter.
Bioinformatic analysis
Processed transcriptomic data form 981 glioma patients
(151 astrocytoma, 109 oligoastrocytoma, 159 oligo-
dendroglioma, and 562 glioblastoma) were obtained
from the work published by Ceccarelli et al. in 2016 at
https://tcga-data.nci.nih.gov/docs/publications/lgggbm_2
015/ [28] (Additional file 1: Tables S2-3). The histogram
of the VEGFA expression of TCGA (Additional file 1:
Figure S8 A) and our cohort (Additional file 1: Figure S8
B) was fitted with two Gaussian functions that represent
two populations: high (green) and low (brown) VEGFA
expression. The middle point between the positions of
the two Gaussian functions was used to define the
threshold between both populations.
Statistics
High-volume data downloaded from the TCGA was
managed using the R programming language.
For smaller datasets, statistical analysis was performed
using a 2-tailed Student t test. Data are presented as
means ± standard deviation and were calculated using
the software package GraphPad Prism v. 5.0. Statistical
values of P > 0.05 were not considered significant.
Results
VEGFA expression level stratifies human glial tumors
To observe the clinical relevance of VEGFA, we first
evaluated its mRNA expression in a cohort of 981 low-
(LGG) and high-grade glioma (HGG) patients [28] (Add-
itional file 1: Tables S2-3). Our results show that the
level of VEGFA expression increased according to the
histopathology degree. Distinct gene expression patterns
were seen in the set of GBM samples, in which two dif-
ferent subgroups—high (green) and low (brown) expres-
sion—could be distinguished. Notably, there were 20%
of GBM patients in the TCGA cohort and 25.9% in our
cohort with low VEGFA levels. In the LGG population,
VEGFA expression presented predominantly low values
(Fig. 1a). Similar data were registered in our GBM co-
hort (N = 73); however, our LGG patients (N = 28)
showed higher values than TCGA samples (Fig. 1b, Add-
itional file 1: Table S1).
Results on VEGFA IHC staining are shown in Fig. 1c,
d. 21.54% cases of de novo GBM and 52.94% of LGG pa-
tients showed rare or no expression of VEGFA protein
(IHC score 0), 35.38% and 29.42% GBM and LGG re-
spectively were scored as (1) localized and the rest of the
patients and all the secondary GBMs had a very high
score (2). Although the mean serum VEGFA concentra-
tions (pg/ml) did not differ significantly between GBM
and LGG, two secretion clusters could be distinguished
in both groups. Moreover, VEGFA secretion values in
both glioma groups were higher than in healthy donors
(P < 0.01) and correlated with the tumor grade (Fig. 1e).
In concordance with the results observed in patients,
distinct clusters based on VEGFA secretion and expres-
sion were detected in ten GBM cell lines, which showed
a high correlation between supernatant VEGFA levels
and mRNA values (Fig. 1f, g and Additional file 1: Figure
S1). Remarkably, these patterns were reproduced in
intracranial xenografts, showing a clear relation between
in vitro and in vivo behavior (Fig. 1h). Together, these
results demonstrate that glioma patients could be di-
vided according to VEGFA expression and secretion
levels.
Specific but not standard bevacizumab doses impair
VEGFA expression and secretion
In view of the importance of VEGFA in the angiogenesis
pathway and to better understand its role in GBM, we se-
lected one representative cell line of each subgroup, U87
as high, U373 as medium, and LN229 as low expression.
The second set of experiments examined the ability of
bevacizumab to inhibit VEGFA secretion in vitro at
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Fig. 1 Different levels of VEGFA expression in two human cohorts, in vitro and in xenograft mice. Analysis of VEGFA mRNA expression in gliomas
grouped according to histological type and grade a by transcriptomic technologies (TCGA cohort, n = 981) and b by QRT-PCR (our cohort, n =
101). Patients were stratified into 2 groups based on VEGFA expression values: high (green) and low (brown). c Representative images from the
immunohistochemical (IHC) analysis of VEGFA in patient tissue microarrays (TMAs). Samples from epileptic patients were used as controls. Scale
bar, 300 μm. d Quantification of the IHC analysis of VEGFA expression in our cohort. Staining was scored as follows: 0 = rare, 1 = localized, and 2 =
diffuse. Data are expressed as the percentage of the number of positive cases/total number of specimens. e VEGFA serum concentration (pg/ml)
prior to surgery in GBM and LGG. Healthy donors were used as controls. Student’s t test **P < 0.01. f Ten glioma cell lines were analyzed for the
secretion of VEGFA to the extracellular media at 72 h by ELISA (cells were seeded at 1500 cells/well as a starting culture density). g Basal VEGFA
mRNA expression from 10 glioma cell lines quantified by QRT-PCR. Data represent the mean ± S.D. of two independent experiments performed in
triplicates. h Representative IHC images of sections obtained from brain intracranial xenografts using anti-VEGFA and anti-human vimentin. Scale
bar, 100 μm
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normoxic and hypoxic conditions. Although bevacizu-
mab could compete with the detection antibody, ELISA
assay is able to measure the total VEGFA present in the
extracellular media [29]. For this purpose, we used a
standard dose (SD; 8.3 μg/ml) which mimics the clinical
administration and a specific dose (Spe) calculated for
each cell line (see Additional file 1: methods section). As
can be seen in Fig. 2a and Additional file 1: Figure S2, the
Spe calculated for each cell line (Additional file 1: Table
S4) is able to neutralize VEGFA secretion in the three cell
cultures studied. Once we evaluated both conditions, nor-
moxia was established for the following experiments. Al-
though VEGFA presence in the extracellular media was
reduced using the SD, its complete inhibition was not
reached. Next, we wondered if the inhibition of extracellu-
lar VEGFA could have an impact on VEGFA expression
levels, as autocrine loop has been described [30]. VEGFA
transcript and protein levels were only decreased using
Spe in U87 and U373 (Fig. 2b, c). Similarly, SD had only a
small effect on cellular VEGFA expression in U87 and
U373, but Spe significantly inhibited the VEGFA
expressed in these cell lines (Fig. 2d). Bevacizumab Spe
did not change the cell morphology (Additional file 1: Fig-
ure S3), and no effects were observed in hMSCs viability
(Additional file 1: Figure S4) showing low toxicity levels.
Our results prove that the neutralization of the secretion
of VEGFA is bevacizumab dose-dependent.
Specific dosage of bevacizumab inhibited HBMEC
migration and tube formation in tumor cells
In an effort to elucidate the underlying mechanism of
bevacizumab in angiogenesis, we exposed HBMECs to
conditioned media (CM) obtained by treating U87,
U373, and LN229 cell lines with standard (SD) or spe-
cific doses (Spe) of bevacizumab. In each case, IgG were
used as a control (C).
The antivascular potential of bevacizumab was first
tested by tube formation assay after 16 h of CM incuba-
tion. As shown in Fig. 3a, the branch reduction number
was only significant when U87 and U373-Spe-CM were
Fig. 2 Specific dose of bevacizumab neutralizes VEGFA secretion. a VEGFA quantification (pg/ml) at 72 h by ELISA of U87, U373, and LN229
treated with specific dose (22 μg/ml, 10 μg/ml, and 0.42 μg/ml, respectively), standard dose Bev (8.3 μg/ml), and IgG as a control. b Evaluation of
the relative expression of VEGFA in treated cell lines by QRT-PCR. Ct values were normalized to GAPDH and β-actin. c The expression of VEGFA
was determined via Western blot after the 72-h treatments. Actin levels were used to normalize. d Immunofluorescence staining of actin-
phalloidin (green) and VEGFA (red), including merged nuclei (DAPI, blue). Scale bar, 200 μm. VEGFA signal intensity quantification per cell is
shown on the bottom. Data are shown as mean ± S.D. and are representative of 2 independent experiments. P values were calculated based on
the 2-tailed 2-sample t test. *P < 0.05, **P < 0.01, ***P < 0.001
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used (P < 0.05). Moreover, U87-Spe-CM mediated the
inhibition of tube formation compared with the U87-C-
CM and SD-CM (P < 0.01, P < 0.05). In the case of
U373-CM, the total network length was reduced using
Spe-CM (P < 0.01). No effect was observed when LN229-
CM was used. These data demonstrate that U87 and
U373-Spe-CM can efficiently reduce HBMEC tube
formation.
To study the cell migratory behavior, we carried out a
transwell migration assay (Fig. 3b). After 3 h, the num-
ber of HBMECs that moved through the membrane with
U87-C-CM was 6.7-fold higher than the number of cells
incubated with U87-Spe-CM (P < 0.01). A similar per-
centage of migrated cells was observed within the U373
group, with statistically significant differences between
the U373-C-CM versus SD and Spe (P < 0.05).
In the cells incubated with LN229-CM, only a slight re-
duction was observed when SD-CM was used (P < 0.05).
These results suggest that the addition of a specific dose of
bevacizumab inhibited the migration of endothelial cells.
Furthermore, a wound healing assay showed that the
addition of bevacizumab reduced HBMEC motility in the
U87 and U373-CM. No changes in cell migration were
observed in the wells incubated with LN229-CM (Fig. 3c).
Consistent with these observations, we noticed a marked
decrease in the HBMEC migration activity using U87 and
U373-Spe-CM by the xCELLigence Real Time Cell
Analyzer (Fig. 3d) (controls without CM are shown in
Additional file 1: Figure S5). Importantly, we found that
Spe-CM causes the disruption of the autocrine VEGF/
VEGFR2 signaling loop as shown in the dramatic decrease
of VEGFR2 expression (Additional file 1: Figure S6).
Altogether, our results indicate a strong decrease in
angiogenesis in vitro after the treatment of U87 and
U373 cells with a specific dose of bevacizumab.
Specific dosage inhibits vascularization of Matrigel plugs
from in vivo mouse models
Once we confirmed that CM from U87 and U373
treated with Spe of bevacizumab is sufficient to switch
off the angiogenesis in vitro, we wondered whether the
pathway would be limited in vivo. We concentrated condi-
tioned media (c-CM) and mixed it with Matrigel and hep-
arin. Then, it was injected into the mouse flanks.
Macroscopic control plug images appeared red, whereas
plugs treated with SD and Spe appeared pale in the three
cell lines studied. The components of the cellular infiltrate
could be observed in H&E and Masson images (Fig. 4a).
The histological analysis demonstrated that the Spe mark-
edly reduced blood vessel growth compared with the con-
trol group in the c-CM obtained from U87 and U373.
Furthermore, the c-CM from U87 Spe and U373 SD and
Spe, but not from LN229, presented a sustained decrease
in neovascularization (Fig. 4b), which was confirmed in
the significant reduction of specific markers for mouse
endothelial cells such as CD31 and von Willebrand factor
(VWF) (Fig. 4c). SD had no inhibition effect in U87. On
the contrary, we observed an increase in endothelial
marker expression (Fig. 4c, d). Analysis of angiogenesis-
related factors (VEGFA, VEGFB, and VEGFR2) in Matri-
gel plugs obtained from c-CM-U87 and c-CM-U373 evi-
denced a high decrease in expression after the addition of
the Spe of bevacizumab. We observed that only the
addition of the Spe reduced VEGFA expression, while the
use of both bevacizumab concentrations diminished
VEGFB and VEGFR2 expression (Fig. 4d). These data con-
firm that the Spe of bevacizumab is needed to inhibit
angiogenesis in vivo.
Specific dosages showed antitumor activity in angiogenic
cell lines
To further confirm that the Spe of bevacizumab could
only reduce tumor growth in high angiogenic cell lines,
we implanted U87, U373, and LN229 subcutaneously
into the flanks of nude mice. Bevacizumab treatment
was administered twice a week following Baumgarten’s
recommendations for dose extrapolations between hu-
man/iv and mice/ip [27]. Remarkably, U87 and U373
tumor volume and growth were drastically suppressed
by SD and in a more significant manner with Spe. How-
ever, bevacizumab treatment did not affect tumoral ac-
tivity in the in vivo xenograft models formed by the low
VEGFA-expressed cell line LN229 (Fig. 5a–c). More im-
portantly, the amount of VEGFA secreted by only tu-
moral cells was quantified from mouse serum using a
human-specific test. Values obtained demonstrate that
SD could only reduce the amount of VEGFA ligand in
the U87 xenograft model, whereas the Spe extended its
capability to U87 and U373 models (P < 0.05). No effect
was detected in LN229 tumors (Fig. 5d).
VEGFA protein expression in tissue was reduced in a
dose-dependent manner in U87 and U373 (P < 0.01). Sur-
prisingly, bevacizumab treatment increased VEGFA expres-
sion in LN229 tissue sections (Fig. 5e). The study of new
blood vessel formation by CD105 confirms that bevacizu-
mab treatment is only effective in cell lines with high
VEGFA secretion (Fig. 5f), confirmed by the substantially
reduced protein levels compared to the control (Fig. 5g).
H&E staining revealed no changes in cell morphology; how-
ever, U373-xenografted mice treated with Spe had lower
cellularity (Additional file 1: Figure S7). Taken together, our
results suggest that two different groups of patients could
be stratified depending on basal VEGFA secretion.
VEGFA serum concentration key to predict the response
to bevacizumab therapy in glioma patients
In order to accomplish our study objective, we selected
the patients treated with bevacizumab following the
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Fig. 3 Specific dose of bevacizumab obtained from U87 and U373 inhibited HBMEC angiogenesis in vitro. a Representative micrographs show
endothelial network formation after 18 h of seeding exposed to conditioned media (CM) from U87, U373, and LN229 treated with IgG (control),
standard dose (SD), and specific dose (Spe) of bevacizumab. Scale bar, 500 μm. Quantification (total number of branches and sum of lengths) of
HBMEC tube formation from three experiments is shown below. The number of branches only significantly decreased with U87 and U373 Spe-
CM (*P < 0.05). The sum of lengths was reduced with U87, U373 SD-CM (*P < 0.05), and Spe-CM (**P < 0.01). b Transwell migration assays of
HBMEC exposed to conditioned media (CM) and to serum-free media (negative control) (Additional file 1: Figure S5A) (*P < 0.05, **P < 0.01). Scale
bar, 250 μm. c Wound width was analyzed 0 and 7 h after wounding. Dotted lines indicate the wound borders. Wound closure is expressed as
the percentage of the width of the initial wound (HBMEC with serum-free media was used as a negative control, Additional file 1: Figure S5B).
Only significant differences were observed in U87 and U373-CM (*P < 0.05 and **P < 0.01, respectively). Scale bar, 500 μm. d HBMEC were seeded
at 4 × 104 cells per well in uncoated wells. Real-time response curves are data from the xCELLigence Real-Time Cell Analyzer System. The gray
curve represents the cells exposed only to serum-free media. Data are shown as mean ± S.D. and are representative of 2 independent
experiments, each performed in triplicate. 2-tailed Student’s t test
Fig. 4 Anti-angiogenic activity of conditioned media using in vivo Matrigel plug assay. Six-week-old nude mice were subcutaneously injected
with Matrigel containing concentrated CM (c-CM). a After 7 days, mice were sacrificed, and representative Matrigel plugs were removed and
photographed. Sections of each Matrigel plug were stained with H&E and Masson’s Trichrome staining. Scale bar, 200 μm. b. The number of
blood vessels was counted by two independent observers and averaged. Quantitative RT-PCR analysis of c CD31 and vWF and d VEGFA, VEGFR2,
and VEGFB expression levels in Matrigel plugs from implanted mice. Less neovascularization was observed in the Matrigel plug of c-CM-Spe. Data
are representative of at least two independent experiments. Data are shown as mean ± S.D. *P < 0.05, **P < 0.01, ***P < 0.001
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scheme depicted in Fig. 6a. The results obtained from
surgical solid biopsy support the idea that some GBM
patients have a tumor with a high angiogenic phenotype
(patients 8 and 2), while in others, VEGFA protein ex-
pression is absent (patient 11) (Fig. 6b). Considering that
there is no consensus for VEGFA measurement in the
peripheral blood, we evaluated it in plasma and serum,
and we observed that the serum mean concentration
was almost 2.5 times the plasma value (Fig. 6c). Interest-
ingly, the correlation between VEGFA expression in
tumor tissue and serum (r = 0.87, P < 0.05) was much
stronger than between the levels in tumor tissue and
plasma (r = 0.75, P = 0.153) (Fig. 6d). To further confirm
this observation, we collected blood prior to and after
bevacizumab treatment. As expected, a strong associ-
ation was shown between VEGFA serum levels, radio-
graphic response, and RANO criteria (Additional file 1:
Table S5). These values correlate with CBVr and Ktrans
and could distinguish between potential bevacizumab re-
sponder (Fig. 6e–i) and non-responder patients (Fig. 6j–
n and Additional file 1: Figure S9). No association was
observed in the plasma (Additional file 1: Figure 1S0).
Discussion
Glioma growth and progression are dependent on neo-
vascularization [31], which involves endothelial cell pro-
liferation, migration, and tube formation [32]. Since
VEGFA is the main pro-angiogenic factor, it has been
used as a target in several pathologies [33]. However, the
clinical benefit in glioma patients has been questioned
considering the results obtained in clinical trials [34],
raising much controversy [35]. Some possible explana-
tions for the lack of therapeutic effects of bevacizumab
are the acquired resistance observed in some patients
and the fact that more than 30% of placebo arm patients
received bevacizumab during disease progression [36].
From our in silico analysis of TCGA data, we observed
two different populations based on VEGFA expression
which were confirmed in mRNA, protein, and serum
levels in our own cohorts. The data suggest that there
are more than 20% of GBM patients whose tumor
growth is independent of the VEGFA pathway, so they
would not benefit from an anti-angiogenic treatment.
Our expression results support the idea that GBM tu-
mors are more angiogenic than LGG [37] and even more
remarkably in recurrent GBM. These differences were
not detected in the peripheral blood, where we observed
similar VEGFA levels between HGG and LGG patients.
However, significant differences were observed com-
pared to healthy donors, confirming that brain tumor
patients release more VEGFA into the bloodstream [38].
As bevacizumab is an antibody that neutralizes the
cytokine VEGFA, we wondered if the benefit from this
agent could correlate with its tumor expression pattern.
Our results showed that there is a group of cell lines
with low VEGFA expression/secretion (GBM27, LN229,
12OCT) that would not be candidates for this anti-
angiogenic treatment as no response was observed with
standard and specific bevacizumab doses in the cell line
that represents that group (LN229). Moreover, VEGFA
expression profiles from these cell lines are maintained
in in vivo models, pointing to their potential use as pre-
clinical models [39]. Focusing on the cell lines that
would respond to bevacizumab therapy, VEGFA tran-
script levels were only significantly reduced using a spe-
cific dose, which highlights the need to optimize
antibody dosing [40, 41]. In this sense, a recent study
has highlighted that adjusting doses of bevacizumab
could increase concomitant chemotherapy delivery [42].
It is known that VEGFA directs binding to its receptor
VEGFR2 and stimulates angiogenesis, endothelial cell
migration, and cancer cell proliferation and survival [43,
44]. Our study confirms that in U87 and U373 GBM
cells treated with the standard dose of bevacizumab,
which mimics clinical administration, the migration of
brain endothelial cells decreases in vitro and in vivo,
with no effect observed in VEGF/VEGFR2 signaling. The
inhibition of this switching loop together with the sig-
nificant reduction in endothelial marker expression and
HBMEC migration was only reached when high VEGFA
cancer cell lines were treated with the specific dose. As
no effect was detected in the LN229 cell line, we specu-
late that cell lines with a low VEGFA expression/secre-
tion values could correspond with non-responder
patients. These data suggest that VEGFA values could
be used as a predictor of bevacizumab dose, increasing
its therapeutic efficacy.
(See figure on previous page.)
Fig. 5 In vivo tumor growth inhibition by a specific dose of bevacizumab in high VEGFA secreted cell lines. a 1.5 × 106 U87, U373, and LN229
cells were implanted into the flanks of nude mice. Mice were treated with IgG (n = 10), SD (n = 5), and a specific dose of bevacizumab (n = 5)
twice a week. Representative macroscopic tumor images of control (left), SD, and Spe (right) are shown. b Tumor volume (mm3) at the endpoint.
c Tumor growth curves. d Human VEGFA measure (pg/ml) from mouse serum. e Immunohistochemistry images using anti-VEGFA antibody, scale
bar 200 μm, and real-time PCR analysis assessing VEGFA expression in tumoral tissue. f Immunofluorescence microscopy using anti-human
vimentin (green) and mouse CD105 (red). The nuclei were stained with DAPI (blue). Scale bar, 100 μm. Relative fluorescence intensity was
calculated for CD105. g Western blots demonstrating that Spe of bevacizumab inhibits VEGFA in U87 and U373 cell lines. Results are shown as
mean ± S.D. *P < 0.05, **P < 0.01, ***P < 0.001
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In this context, one of the challenges is to distinguish
between VEGFA released from tumoral cells and other
sources [45]. The amount of hVEGFA measured in the
serum from our xenograft mouse models corroborates
that a specific dose was more effective than the standard
dose in pro-angiogenic cell lines. We show that this treat-
ment impairs tumor growth and results in less vascula-
ture. In contrast, none of the bevacizumab dosages had an
effect on the cell line with low VEGFA values, confirming
our in vitro results. These data have several therapeutic
implications, as some patients might not require bevacizu-
mab treatment, while others need an adjusted dosage.
In this regard, several approaches have been studied to
identify which patients would benefit from this treatment,
for example, VEGFA plasma levels were measured prior
to treatment in AVAGLIO cohort [46], and high VEGFA
expression in tissue was correlated with the radiographic
response in some patients [47]. However, no association
was observed with patient outcomes. In contrast, we and
others have shown that VEGFA plasma values do not rep-
resent the real angiogenic tumor status [48]. For this rea-
son, as there are no established biomarkers to predict
response to bevacizumab therapy, we propose the analysis
of VEGFA in the original tissue and serum to help in
patient stratification and to identify the mechanisms of re-
sistance and escape routes [49, 50]. Moreover, the analysis
of VEGFA in serum could help monitor disease progres-
sion and treatment efficacy, supporting MRI data.
Future experiments monitoring VEGFA serum levels
with larger cohorts would be required to confirm these
effects and to observe differences in the OS, and al-
though our small cohort is highly representative, bevaci-
zumab is not approved by the European Medicines
Agency (EMA) [51]. To overcome this issue, we analyzed
the OS in the GBM-IDHwt TCGA cohort and divided
the cohort based on the VEGFA expression into high
and low clusters (Additional file 1: Table S6). Interest-
ingly, when we divided the cohort according to treat-
ment criteria, we did not see differences in OS in the full
population (Additional file 1: Figure S11A). However,
the median OS of patients with high VEGFA treated
with bevacizumab increased in 8.5 months (Add-
itional file 1: Figure S11C), and no effect was observed
in patients with low VEGFA expression (Additional file 1:
Figure S11B).
Although this is only a proof of concept, since those
patients received a multimodal therapy including several
drugs, this novel approach could indicate a change in
the paradigm of GBM patients’ care.
Conclusion
Our results show that adjusting bevacizumab posology
could be a successful strategy to further predict response
stratification. Moreover, we propose to measure the
amount of VEGFA in serum and not in plasma to en-
hance treatment efficacy.
Supplementary information
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1186/s12916-020-01610-0.
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